Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

For Further Information Contact: Paul Averback Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12 HASBROUCK HEIGHTS, NJ (October 10, 2017) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report on the Symposium on Fexapotide Triflutate studi es to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week. The symposium, “Fexapotide Triflutate: A Safe and Effective First In Class Injectable for BPH” w ill be chaired by James Bailen MD FACS of Louisville, KY. The other panel members at the Symposium will be Dr. Franklin D. Gaylis of San Diego CA, Dr. Stephen Richardson of Salt Lake City UT, and Dr. Jed Kaminetsky of New York NY. The Symposium will present detailed clinical data on the Phase 3 clinical trials th at have been completed for Fexapotide and that have shown excellent safety and significant efficacy for the treatment of BPH. In addition, scientific data supporting the safety and efficacy from non-clinical and laboratory testing and analysis will be demonstrated. The main presentation will be followed by a panel discussion and by an interactive question and answer session with the specialist doctors in attendance. Nymox's lead drug Fexapotide has been in development for over 10 years and has been te sted by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind st udies of treatment of 995 U.S. men with prostate enlargement to not only show clinically meaningful and du rable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical pr ogram has also shown in a long-term blinded placebo crossover group study an 82-95% reduction in the number of these patients who required surgery after they received crossover Fexapotide in the trial, as compared to patients who did not rece ive Fexapotide but instead received crossover conventional approved BPH treatments (p<.0001). For more information please contact [email protected] or 800-936-9669. Forward Looking Statements To the extent that statements contained in this press rel ease are not descriptions of historical facts regarding Nymox, they ar e forward-looking statements reflecting t he current beliefs and expectations of mana gement made pursuant to the safe harbor provisions of the Private Secu rities Litigation Reform Act of 1995, including st atements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to tr eat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements invo lve substantial risks and uncert ainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinic al drug development process, including the r egulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapot ide, Nymox's commercialization plans and effort s and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause ac tual results to differ from those expressed in these forward-looking statem ents, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports. NEWS RELEASE

The release as fetched from its publisher. nymox.com ↗